Alcon’s Net Sales Grow 8 Percent in Q4-2017, 4 Percent for Full Year

February 2, 2018: By Jon Swedien

Alcon’s net sales for Q4-2017 were $1.56 billion (8 percent, 6 percent cc), parent company Novartis reported Jan. 24.

Alcon’s net sales for the full year were $6 billion (4 percent, 4 percent cc), Novartis reported.

Annual surgical sales were $3.7 billion, up 5 percent (cc), Novartis said in its 2017 annual report. The growth was mainly due to strong performance of products in the vitreoretinal portfolio and growth in cataract disposable surgical supplies, Novartis said.

Vision Care sales were $2.4 billion (3 percent, cc), Novartis said.

CEO Vasant Narasimhan said Novartis is still considering a possible spinoff of Alcon in the first half of 2019. Narasimhan took over for former CEO Joseph Jimenez on Feb. 1.

“We are making progress toward the capital market exit with dedicated teams working toward that,” Narasimhan said in a Jan. 24 earnings call. “But there is no change on the timing of a potential action; we continue to guide toward the potential action in the first half of 2019.”

Novartis posted $12.9 billion (5 percent, 2 percent cc) in Q4-2017. The company’s net sales for the full year were $49 billion (1 percent, 2 percent cc).

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility